BR9507451A - Pharmaceutical composition use of an amount of (i) a standardized antigen together with an amount of (ii) a polypeptide and product containing an amount of (i) a standardized antigen together with an amount of (ii) a polypeptide - Google Patents
Pharmaceutical composition use of an amount of (i) a standardized antigen together with an amount of (ii) a polypeptide and product containing an amount of (i) a standardized antigen together with an amount of (ii) a polypeptideInfo
- Publication number
- BR9507451A BR9507451A BR9507451A BR9507451A BR9507451A BR 9507451 A BR9507451 A BR 9507451A BR 9507451 A BR9507451 A BR 9507451A BR 9507451 A BR9507451 A BR 9507451A BR 9507451 A BR9507451 A BR 9507451A
- Authority
- BR
- Brazil
- Prior art keywords
- amount
- polypeptide
- antigen together
- standardized antigen
- standardized
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rehabilitation Therapy (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22537294A | 1994-04-08 | 1994-04-08 | |
PCT/US1995/004120 WO1995027499A1 (en) | 1994-04-08 | 1995-04-07 | Treatment of autoimmune disease using oral tolerization and/or type i interferon |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9507451A true BR9507451A (en) | 1997-08-05 |
Family
ID=22844605
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9507451A BR9507451A (en) | 1994-04-08 | 1995-04-07 | Pharmaceutical composition use of an amount of (i) a standardized antigen together with an amount of (ii) a polypeptide and product containing an amount of (i) a standardized antigen together with an amount of (ii) a polypeptide |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0752880A4 (en) |
JP (1) | JPH09511745A (en) |
AU (1) | AU686797B2 (en) |
BR (1) | BR9507451A (en) |
CA (1) | CA2185353A1 (en) |
HU (1) | HUT74900A (en) |
IL (1) | IL113303A0 (en) |
NO (1) | NO964199D0 (en) |
WO (1) | WO1995027499A1 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5906816A (en) * | 1995-03-16 | 1999-05-25 | University Of Florida | Method for treatment of autoimmune diseases |
US6372206B1 (en) | 1989-03-02 | 2002-04-16 | University Of Florida | Orally-administered interferon-TAU compositions and methods |
WO1996012737A2 (en) * | 1994-10-25 | 1996-05-02 | Immulogic Pharmaceutical Corporation | Compositions and treatment for multiple sclerosis |
CA2275890C (en) * | 1996-12-24 | 2011-11-01 | Biogen, Inc. | Stable liquid interferon formulations |
CA2252790A1 (en) * | 1997-02-28 | 1998-09-03 | Enzo Therapeutics, Inc. | Novel processes implementing selective immune down regulation (sidr) |
ES2382488T3 (en) | 1997-03-21 | 2012-06-08 | Chugai Seiyaku Kabushiki Kaisha | A preventive or therapeutic agent for diseases mediated by sensitized t cells comprising an il-6 antagonist as an active ingredient |
US6812205B2 (en) | 2000-03-15 | 2004-11-02 | The Brigham & Women's Hospital, Inc. | Suppression of vascular disorders by mucosal administration of heat shock protein peptides |
JP4986361B2 (en) | 2000-05-24 | 2012-07-25 | ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ シークレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ | Stroke prevention method by induction of tolerance to E-selectin |
CA2511209A1 (en) * | 2002-12-26 | 2004-07-15 | Daiichi Suntory Pharma Co., Ltd. | Agent for treatment of pemphigoid |
AU2007351813B2 (en) | 2006-10-31 | 2013-10-10 | East Carolina University | Fusion proteins comprising an anti-inflammatory cytokine and an antigen for treatment of immune disorders |
EP2413958A4 (en) | 2009-03-31 | 2014-04-02 | Univ East Carolina | Cytokines and neuroantigens for treatment of immune disorders |
JP6590330B2 (en) * | 2013-11-11 | 2019-10-16 | キッコーマン株式会社 | Oral immune tolerance enhancing substance screening method and oral immune tolerance enhancing composition |
GB201904767D0 (en) | 2019-04-04 | 2019-05-22 | Orexo Ab | New pharmaceutical compositions |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2844889A (en) * | 1988-01-22 | 1989-07-27 | Collagen Corporation | Method for suppressing the growth of normal and cancer cells |
DK0627933T3 (en) * | 1992-02-28 | 2003-03-24 | Autoimmune Inc | Bystander suppression of autoimmune diseases |
-
1995
- 1995-04-07 EP EP95916183A patent/EP0752880A4/en not_active Withdrawn
- 1995-04-07 AU AU22776/95A patent/AU686797B2/en not_active Ceased
- 1995-04-07 BR BR9507451A patent/BR9507451A/en unknown
- 1995-04-07 IL IL11330395A patent/IL113303A0/en unknown
- 1995-04-07 HU HU9602750A patent/HUT74900A/en active IP Right Revival
- 1995-04-07 JP JP7526403A patent/JPH09511745A/en active Pending
- 1995-04-07 CA CA002185353A patent/CA2185353A1/en not_active Abandoned
- 1995-04-07 WO PCT/US1995/004120 patent/WO1995027499A1/en active Search and Examination
-
1996
- 1996-10-03 NO NO964199A patent/NO964199D0/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP0752880A1 (en) | 1997-01-15 |
HUT74900A (en) | 1997-02-28 |
IL113303A0 (en) | 1995-07-31 |
CA2185353A1 (en) | 1995-10-19 |
AU2277695A (en) | 1995-10-30 |
HU9602750D0 (en) | 1996-11-28 |
AU686797B2 (en) | 1998-02-12 |
WO1995027499A1 (en) | 1995-10-19 |
NO964199L (en) | 1996-10-03 |
NO964199D0 (en) | 1996-10-03 |
JPH09511745A (en) | 1997-11-25 |
EP0752880A4 (en) | 2000-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9607317A (en) | Peptides and pharmaceutical composition | |
BR9607318A (en) | Peptides and pharmaceutical composition | |
FI963185A (en) | Hematopoietic protein and materials and methods for its preparation | |
BR1100824A (en) | Pharmaceutical composition and composition | |
FI972657A0 (en) | Aerosol formulations of proteins and peptides | |
IL115484A (en) | Polypeptide derivatives processes for the preparation thereof and pharmaceutical compositions containing the same | |
HU9802116D0 (en) | 19-nor-d-vitamin compounds with biologically effect and pharmaceutical compositions containing them | |
FI943565A (en) | Novel anticoagulant polypeptides, their preparation and pharmaceutical composition containing them | |
IL93090A0 (en) | Platinum compounds and pharmaceutical compositions containing the same | |
IT8948460A0 (en) | ADHESIVE COMPOSITION FOR DENTAL PROSTHESES AND PROCEDURE FOR ITS PREPARATION | |
IL117349A0 (en) | N-(3-benyofuranyl) urea-derivatives their preparation and pharmaceutical compositions containing them | |
BR9507451A (en) | Pharmaceutical composition use of an amount of (i) a standardized antigen together with an amount of (ii) a polypeptide and product containing an amount of (i) a standardized antigen together with an amount of (ii) a polypeptide | |
BR9610821A (en) | Amino acid derivative use of a compound and medicine containing the same | |
BR9507452A (en) | Pharmaceutical composition use of a non-interferon polypeptide use of a quantity of a standardized antigen and a quantity of a non-interferon polypeptide and product containing (1) a quantity of a standardized antigen and (11) a quantity of a non-interferon polypeptide | |
IT8922164A0 (en) | PHARMACEUTICAL COMPOSITION AND PROCEDURE FOR ITS PREPARATION | |
DE69522188T2 (en) | Use of substance P antagonist in pharmaceutical composition | |
DE69512929T2 (en) | AMINO ALCOHOL SALTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
IL113484A0 (en) | Viral proteins pharmaceutical compositions containing them their preparation and use | |
IL93727A0 (en) | Pharmaceutical compositions containing polyoxometallate and certain such compounds | |
BR9607757A (en) | Defective recombinant virus adenovirus use of a virus and pharmaceutical composition | |
DK439589D0 (en) | FLUOR-SUBSTITUTED 4'-DEMETHYLEPIPODOPHYLLOTOX INGREDIENTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME | |
BR9604938A (en) | Recombinant virus deficient use of this virus pharmaceutical composition and mammalian cell | |
IT9019536A0 (en) | PROCEDURE FOR THE PREPARATION OF MIXED ZIRCONIUM AND YTTRUM OXIDES | |
EE9400337A (en) | Pharmaceutical compositions containing interferon alpha and their uses | |
AU3893389A (en) | Oxaza heterocycles and pharmaceutical compositions containing same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |